Pulmonary arterial hypertension
Pulmonary arterial hypertension, or PAH, is one type of pulmonary hypertension. MeSH describes it as a progressive, rare lung disease marked by high blood pressure in the pulmonary artery. NHLBI lists it as the first of five groups of pulmonary hypertension and says that worldwide over half of cases have no known cause.
Also called PAH
- Condition
- In this atlas
Overview
Technical summary
MeSH D000081029 is named Pulmonary Arterial Hypertension; its scope note describes a progressive rare pulmonary disease characterized by high blood pressure in the pulmonary artery. MedlinePlus says the types of pulmonary hypertension are based on what caused the disease.
Burden
No burden claims are published.
Claims and evidence
Context People with deep vein thrombosis, pulmonary embolism, peripheral artery disease or pulmonary hypertension, as described in MedlinePlus and NHLBI patient pages
- Recipient
- Recipient not specified
- Population
- People with the condition each page covers. The pages give no age limits and no inclusion criteria.
- Care setting
- Not stated; patient information pages
- Geography
- Not stated; United States federal health agencies (NLM and NIH)
- Life stage
- Not stated on the pages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (descriptive pages)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
MeSH describes pulmonary arterial hypertension as a progressive, rare lung disease marked by high blood pressure in the pulmonary artery. MedlinePlus lists it as one type of pulmonary hypertension, and says the types are based on what caused the disease. NHLBI lists it as the first of five groups of pulmonary hypertension and says that worldwide over half of cases have no known cause.
Applies to Recipient not specified People with deep vein thrombosis, pulmonary embolism, peripheral artery disease or pulmonary hypertension, as described in MedlinePlus and NHLBI patient pages
- Certainty method
- Not assessed
- Limitations
- Patient-education pages from US government sources. They give no study, no size of risk and no population, and they do not say how often any of this happens. The NHLBI proportion is a worldwide figure that the page does not source.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
Supports MeSH scope note for descriptor D000081029 (Pulmonary Arterial Hypertension)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
0d86e2a395a34cb0e3eaf9ab19c77e0acee1f2208e7d2c0004f7dc5c13ac4074- Reuse basis
- The NLM web policies page (fetched 2026-10-30, sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
-
Supports Pulmonary Hypertension (MedlinePlus health topic)
- Locator
- What is pulmonary hypertension?, paragraph 4, sentence 1
- How it applies
- MedlinePlus: PAH is one type.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
25f50e785cf52e29bca0ff8871800a088148f9f83265f6b327951b83f37a0fda- Reuse basis
- MedlinePlus says its summaries on health topic pages are in the public domain and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Pulmonary Hypertension (MedlinePlus health topic)
- Locator
- What is pulmonary hypertension?, paragraph 4, sentence 2
- How it applies
- MedlinePlus: types are based on cause.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
25f50e785cf52e29bca0ff8871800a088148f9f83265f6b327951b83f37a0fda- Reuse basis
- MedlinePlus says its summaries on health topic pages are in the public domain and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Pulmonary Hypertension: What Is Pulmonary Hypertension? (NHLBI)
- Locator
- What Is Pulmonary Hypertension?, group list item 1
- How it applies
- NHLBI: group 1 of five. Last updated May 01, 2023 according to the page.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
98fd71a76fdb8f2f17300792080a72f854e2b80953ac5c23501dcf46efa92b8b- Reuse basis
- NHLBI is part of the U.S. National Institutes of Health. The pages carry third-party material, such as animations credited to Nucleus Medical Media, that this atlas does not use. NHLBI's own reuse terms were not read, so public text is cite_only until they are read; the rule can then change to quote. Hash only; the page is not committed.
-
Supports Pulmonary Hypertension: What Is Pulmonary Hypertension? (NHLBI)
- Locator
- What Is Pulmonary Hypertension?, paragraph 3
- How it applies
- NHLBI: over half of cases have no known cause.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
98fd71a76fdb8f2f17300792080a72f854e2b80953ac5c23501dcf46efa92b8b- Reuse basis
- NHLBI is part of the U.S. National Institutes of Health. The pages carry third-party material, such as animations credited to Nucleus Medical Media, that this atlas does not use. NHLBI's own reuse terms were not read, so public text is cite_only until they are read; the rule can then change to quote. Hash only; the page is not committed.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Ambrisentan
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Letairis
Population, setting and follow-up
- Adult patients with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Letairis (ambrisentan tablets, Gilead Sciences, Inc., application NDA022081; the version dated 2026-06-22 in openFDA) describes ambrisentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients to improve exercise ability and delay clinical worsening.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists use in combination with tadalafil; that indication is not recorded here. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a use in combination with tadalafil; that use is not recorded here.
-
Claim, not a settled fact Evaluated for this: Bosentan
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Tracleer
Population, setting and follow-up
- Adults with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Tracleer (bosentan tablets and tablets for oral suspension, Actelion Pharmaceuticals US, Inc., applications NDA021290 and NDA209279; the version dated 2025-11-17 in openFDA) describes bosentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a pediatric use, which sits in a separate claim.
-
Claim, not a settled fact Evaluated for this: Bosentan
Applies to Child Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as described in the US label of Tracleer
Population, setting and follow-up
- Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients aged 3 years and older, as the label states
- Gestational age Not reported
- Postnatal age Not reported
The same US label of Tracleer separately lists treating pulmonary arterial hypertension in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, to improve pulmonary vascular resistance.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The adult use is in a separate claim. The label's own sentence that the improvement in pulmonary vascular resistance is expected to result in better exercise ability was not recorded.
-
Claim, not a settled fact Evaluated for this: Macitentan
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Opsumit
Population, setting and follow-up
- Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Opsumit (macitentan tablets, Actelion Pharmaceuticals US, Inc., application NDA204410; the version dated 2025-04-11 in openFDA) describes macitentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group I) in adults to reduce the risks of disease progression and hospitalization for pulmonary arterial hypertension.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Riociguat
Applies to Adult Adults with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension, as described in the US label of Adempas
Population, setting and follow-up
- Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable disease (WHO Group 4), and adults with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Adempas (riociguat tablets, Bayer HealthCare Pharmaceuticals Inc., application NDA204819; the version dated 2026-08-13 in openFDA) describes riociguat as a soluble guanylate cyclase stimulator. It lists treating adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and adults with pulmonary arterial hypertension (WHO Group 1), to improve exercise capacity.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists improving WHO functional class and delaying clinical worsening; only the exercise capacity wording is quoted here.
-
Claim, not a settled fact Evaluated for this: Selexipag
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Uptravi
Population, setting and follow-up
- Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Uptravi (selexipag, Actelion Pharmaceuticals US, Inc., applications NDA207947 and NDA214275; the version dated 2026-05-28 in openFDA) describes selexipag as a prostacyclin receptor agonist. It lists treating pulmonary arterial hypertension (PAH, WHO Group I) in adults to delay disease progression and lower the risk of hospital admission for PAH.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
-
Claim, not a settled fact Evaluated for this: Selexipag
Applies to Child Pediatric patients aged 2 years and older with pulmonary arterial hypertension, as described in the US label of Uptravi
Population, setting and follow-up
- Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients aged two years and older, as the label states
- Gestational age Not reported
- Postnatal age Not reported
The same US label of Uptravi separately lists treating pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged two years and older. The label says Uptravi reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH.Limitations. The label words the pediatric benefit as expected, and this claim keeps that wording. It is not a finding about how well the medicine works in children. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
-
Claim, not a settled fact Evaluated for this: Sildenafil
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Revatio
Population, setting and follow-up
- Adults with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Revatio (sildenafil citrate, Viatris Specialty LLC, applications NDA203109, NDA022473 and NDA021845; the version dated 2024-12-18 in openFDA) lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.Limitations. This claim is tied to the Revatio label for pulmonary arterial hypertension. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
-
Claim, not a settled fact Evaluated for this: Sildenafil
Applies to Child Pediatric patients 1 to 17 years old with pulmonary arterial hypertension, as described in the US label of Revatio
Population, setting and follow-up
- Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients 1 to 17 years old, as the label states
- Gestational age Not reported
- Postnatal age Not reported
The same US label of Revatio separately lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old, to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, a measure of pulmonary hemodynamics.Limitations. This claim is tied to the Revatio label for children aged 1 to 17 years. It says nothing about newborns or children under 1 year. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
-
Claim, not a settled fact Evaluated for this: Sotatercept
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Winrevair
Population, setting and follow-up
- Adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Winrevair (sotatercept-csrk, Merck Sharp & Dohme LLC, application BLA761363; the version dated 2026-09-21 in openFDA) describes the medicine as an activin signaling inhibitor. It lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and to reduce the risk of clinical worsening events.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
-
Claim, not a settled fact Evaluated for this: Tadalafil
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US labels of Adcirca and Alyq
Population, setting and follow-up
- Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the labels state. The passage read gives no age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Adcirca (tadalafil, United Therapeutics Corporation, application NDA022332; the version dated 2025-12-15 in openFDA) calls the medicine a phosphodiesterase 5 (PDE5) inhibitor. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. The US label of Alyq (tadalafil tablets, Teva Pharmaceuticals, Inc., application ANDA216932; the version dated 2023-04-01 in openFDA) lists the same use.Limitations. This claim is tied to the two pulmonary arterial hypertension labels named. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
-
Claim, not a settled fact Evaluated for this: Treprostinil
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Remodulin
Population, setting and follow-up
- Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the passage read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Remodulin (treprostinil injection, United Therapeutics Corporation, application NDA021272; the version dated 2026-07-02 in openFDA) calls the medicine a prostacyclin mimetic, formulated for subcutaneous or intravenous administration. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.Limitations. This claim is tied to the Remodulin injection label only. The inhaled and oral treprostinil products have their own labels and claims. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a transition use, which sits in a separate claim.
-
Claim, not a settled fact Evaluated for this: Treprostinil
Applies to Recipient not specified Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin
Population, setting and follow-up
- Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the passage read
- Gestational age Not reported
- Postnatal age Not reported
The same US label of Remodulin separately lists, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration.Limitations. This claim is tied to the Remodulin injection label only, and to the transition use the label names. It does not say how a transition is done, and no instruction is recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
-
Claim, not a settled fact Evaluated for this: Treprostinil
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso
Population, setting and follow-up
- Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the passage read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Tyvaso (treprostinil, a sterile solution for oral inhalation, United Therapeutics Corporation, application NDA022387; the version dated 2026-04-14 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.Limitations. This claim is tied to the Tyvaso inhalation solution label only. Other inhaled treprostinil products have their own labels and were not read. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists pulmonary hypertension with interstitial lung disease, which sits in a separate claim.
-
Claim, not a settled fact Evaluated for this: Treprostinil
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Orenitram
Population, setting and follow-up
- Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the passage read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Orenitram (treprostinil extended-release tablets, United Therapeutics Corporation, application NDA203496; the version dated 2024-11-20 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.Limitations. This claim is tied to the Orenitram tablet label only. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 60
Record details
- Record id
cardio:pulmonary-arterial-hypertension- Content hash
cfb4d9b6f163215c45cf543ed360d8de01740a4d48363738515887bc885d6721